Previous 10 | Next 10 |
Summary IDEAYA caught a bid in the back end of FY22' as investors began to take notice of advancements in its clinical pipeline. The rally seems to have flattened into the new year, so we wanted to check if there's scope for it to extend further. The company's investigational compou...
IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused prec...
IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board PR Newswire - Dr. Karlene Cimprich , Ph.D. ( Stanford University ), is a leading scientist in replication stress mechanisms and regulati...
IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK PR Newswire Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed comple...
The biotech bear market has been particularly hard on Precision Oncology companies - particularly those that came to market on the back of lucrative IPOs. Ideaya IPO'd in 2019, raising a modest $55m, and it continues to trade above its IPO price of $10, which is rare. Shares hit a hig...
IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , June 8, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology comp...
Roth Capital Partners is raising its price target on Ideaya Biosciences (NASDAQ:IDYA) to a Street high of $46 from $42 (341% upside based on Monday's close) while maintaining a buy rating. Analyst Zegbeh Jallah said that the company is well positioned following the recent release of Q1 2...
IDEAYA Biosciences press release (NASDAQ:IDYA): Q1 GAAP EPS of -$0.36 beats by $0.06. Revenue of $11.36M (+57.8% Y/Y) beats by $5.03M. Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of March 31, 2022 is anticipated to fund planned operations into 202...
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update PR Newswire Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of March 31, 2022 is anticipated to fund planned operations ...
IDEAYA Biosciences to Participate in Investor Conferences in May 2022 PR Newswire SAN FRANCISCO , May 3, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the disco...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...